Protalix BioTherapeutics (PLX +0.7%) says its the first patient has been treated in its Phase...

|About: Protalix BioTherapeutics, Inc (PLX)|By:, SA News Editor

Protalix BioTherapeutics (PLX +0.7%) says its the first patient has been treated in its Phase I/II clinical trials of PRX-102, its plant cell-expressed, chemically modified enzyme replacement therapy for the treatment of Fabry disease.